Third dose of coronavirus disease 2019 vaccination in liver transplantation recipients
Won Sriwijitalai, Viroj Wiwanitkit – 21 April 2022
Erratum
21 April 2022
Masthead
21 April 2022
Identification of the chloride channel, leucine‐rich repeat‐containing protein 8, subfamily a (LRRC8A), in mouse cholangiocytes
Nikolay Shcheynikov, Kristy Boggs, Anthony Green, Andrew P. Feranchak – 20 April 2022
CAQ Corner: Long‐term medical complications of liver transplantation
Monica Tincopa – 20 April 2022
First‐line therapies for hepatitis B in the United States: A 3‐year prospective and multicenter real‐world study after approval of tenofovir alefenamide
Calvin Q. Pan, Nezam H. Afdhal, Victor Ankoma‐Sey, Ho Bae, Michael P. Curry, Douglas Dieterich, Lynn Frazier, Andrew Frick, Hie‐Won Hann, W. Ray Kim, Paul Kwo, Scott Milligan, Myron J. Tong, K. Rajender Reddy – 20 April 2022 – Real‐world data are limited on tenofovir alafenamide (TAF). We aimed to study TAF real‐world outcomes with other first‐line regimens for chronic hepatitis B (CHB). We enrolled patients with CHB from 10 centers retrospectively and followed them for 36 months prospectively.
Neutralization and receptor use of infectious culture–derived rat hepacivirus as a model for HCV
Raphael Wolfisberg, Caroline E. Thorselius, Eduardo Salinas, Elizabeth Elrod, Sheetal Trivedi, Louise Nielsen, Ulrik Fahnøe, Amit Kapoor, Arash Grakoui, Charles M. Rice, Jens Bukh, Kenn Holmbeck, Troels K. H. Scheel – 20 April 2022
Letter to the editor: A revised electronic version of RUCAM for the diagnosis of drug‐induced liver injury
Harshad Devarbhavi, Sunu Sara Kurien – 20 April 2022